Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib

Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib

In clinical trials testing abemaciclib in patients with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer, diarrhea is a very common adverse event (occurring in approximately 85% of patients, any grade). Nonetheless, this toxicity leads to abemaciclib discontinuation in a...

Full description

Bibliographic Details
Main Authors: Flavia Jacobs, Elisa Agostinetto, Alessandra Solferino, Rosalba Torrisi, Giovanna Masci, Armando Santoro, Rita De Sanctis
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Journal of Clinical Medicine
Subjects:
diarrhea
supportive care
breast cancer
CDK4/6 inhibitors
abemaciclib
Online Access:https://www.mdpi.com/2077-0383/12/5/1775

Internet

https://www.mdpi.com/2077-0383/12/5/1775

Similar Items